vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $339.0M, roughly 1.4× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -10.1%, a 23.3% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 0.4%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CLOV vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $487.7M | $339.0M |
| Net Profit | $-49.3M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | -10.1% | 19.9% |
| Net Margin | -10.1% | 13.2% |
| Revenue YoY | 44.7% | -2.7% |
| Net Profit YoY | -123.2% | 19.3% |
| EPS (diluted) | — | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $487.7M | $339.0M | ||
| Q3 25 | $496.6M | $327.3M | ||
| Q2 25 | $477.6M | $321.4M | ||
| Q1 25 | $462.3M | $330.6M | ||
| Q4 24 | $337.0M | $348.5M | ||
| Q3 24 | $331.0M | $345.5M | ||
| Q2 24 | $356.3M | $336.2M | ||
| Q1 24 | $346.9M | — |
| Q4 25 | $-49.3M | $44.7M | ||
| Q3 25 | $-24.4M | $38.7M | ||
| Q2 25 | $-10.6M | $34.0M | ||
| Q1 25 | $-1.3M | $58.0M | ||
| Q4 24 | $-22.1M | $37.5M | ||
| Q3 24 | $-9.2M | $33.8M | ||
| Q2 24 | $7.4M | $38.4M | ||
| Q1 24 | $-19.2M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | 24.5% | 54.2% | ||
| Q2 24 | 30.3% | 52.0% | ||
| Q1 24 | 23.6% | — |
| Q4 25 | -10.1% | 19.9% | ||
| Q3 25 | -4.9% | 17.9% | ||
| Q2 25 | -2.2% | 16.8% | ||
| Q1 25 | -0.3% | 21.6% | ||
| Q4 24 | -6.4% | 16.9% | ||
| Q3 24 | -2.7% | 15.0% | ||
| Q2 24 | 2.0% | 11.8% | ||
| Q1 24 | -6.5% | — |
| Q4 25 | -10.1% | 13.2% | ||
| Q3 25 | -4.9% | 11.8% | ||
| Q2 25 | -2.2% | 10.6% | ||
| Q1 25 | -0.3% | 17.5% | ||
| Q4 24 | -6.6% | 10.8% | ||
| Q3 24 | -2.8% | 9.8% | ||
| Q2 24 | 2.1% | 11.4% | ||
| Q1 24 | -5.5% | — |
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.70 | ||
| Q1 25 | — | $1.17 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | — | $0.66 | ||
| Q2 24 | — | $0.74 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.3M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $308.7M | $911.5M |
| Total Assets | $541.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.3M | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | $194.5M | $320.8M | ||
| Q3 24 | $288.0M | $299.3M | ||
| Q2 24 | $254.8M | $344.4M | ||
| Q1 24 | $208.3M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $308.7M | $911.5M | ||
| Q3 25 | $340.9M | $849.2M | ||
| Q2 25 | $344.2M | $882.3M | ||
| Q1 25 | $336.1M | $820.8M | ||
| Q4 24 | $341.1M | $906.9M | ||
| Q3 24 | $342.2M | $878.9M | ||
| Q2 24 | $324.9M | $905.4M | ||
| Q1 24 | $292.5M | — |
| Q4 25 | $541.0M | $2.5B | ||
| Q3 25 | $559.7M | $2.4B | ||
| Q2 25 | $575.0M | $2.5B | ||
| Q1 25 | $583.7M | $2.5B | ||
| Q4 24 | $580.7M | $2.5B | ||
| Q3 24 | $653.0M | $2.5B | ||
| Q2 24 | $674.2M | $2.5B | ||
| Q1 24 | $671.8M | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-66.9M | $93.6M |
| Free Cash FlowOCF − Capex | $-69.0M | $87.2M |
| FCF MarginFCF / Revenue | -14.1% | 25.7% |
| Capex IntensityCapex / Revenue | 0.4% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-69.2M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-66.9M | $93.6M | ||
| Q3 25 | $12.1M | $111.3M | ||
| Q2 25 | $5.4M | $17.4M | ||
| Q1 25 | $-16.3M | $116.6M | ||
| Q4 24 | $34.8M | $43.8M | ||
| Q3 24 | $50.0M | $48.8M | ||
| Q2 24 | $44.8M | $-27.4M | ||
| Q1 24 | $25.9M | — |
| Q4 25 | $-69.0M | $87.2M | ||
| Q3 25 | $11.4M | $106.3M | ||
| Q2 25 | $4.8M | $13.6M | ||
| Q1 25 | $-16.5M | $100.9M | ||
| Q4 24 | $33.3M | $35.2M | ||
| Q3 24 | $49.6M | $39.4M | ||
| Q2 24 | $44.4M | $-33.1M | ||
| Q1 24 | $25.5M | — |
| Q4 25 | -14.1% | 25.7% | ||
| Q3 25 | 2.3% | 32.5% | ||
| Q2 25 | 1.0% | 4.2% | ||
| Q1 25 | -3.6% | 30.5% | ||
| Q4 24 | 9.9% | 10.1% | ||
| Q3 24 | 15.0% | 11.4% | ||
| Q2 24 | 12.5% | -9.8% | ||
| Q1 24 | 7.3% | — |
| Q4 25 | 0.4% | 1.9% | ||
| Q3 25 | 0.1% | 1.5% | ||
| Q2 25 | 0.1% | 1.2% | ||
| Q1 25 | 0.0% | 4.7% | ||
| Q4 24 | 0.5% | 2.5% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 0.1% | 1.7% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | 6.04× | -0.71× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
